Description of the active substance:
This information is a reference and it is not enough that the drug has been prescribed by a doctor ..
PHARMACHOLOGIC EFFECT
Cephalosporin antibiotic III generation of a broad spectrum of action. Has a bactericidal effect by inhibiting the synthesis of the bacterial cell wall. Ceftriaxone acetylates membrane-bound transpeptidases, thus violating the cross-linking of peptidoglycans necessary to ensure the strength and rigidity of the cell wall.
It is active against aerobic, anaerobic, gram-positive and gram-negative bacteria.
Resistant to the action of? -lactamases.
PHARMACOKINETICS
Binding to plasma proteins is 85-95%. Ceftriaxone is widely distributed in tissues and body fluids. Therapeutic concentrations are achieved in the cerebrospinal fluid with meningitis. High concentrations are achieved in bile. Penetrates through the placental barrier, excreted in breast milk in small amounts. About 40-65% of ceftriaxone is excreted unchanged in urine. The rest is excreted with bile and feces.
INDICATIONS
Infectious-inflammatory diseases caused by microorganisms sensitive to ceftriaxone, incl. peritonitis, sepsis, meningitis, cholangitis, gallbladder empyema, shigellosis, salmonella, pneumonia, lung abscess, pleural empyema, pyelonephritis, infections of bones, joints, skin and soft tissues, genitalia, infected wounds and burns.
Prevention of postoperative infection.
DOSING MODE
Individual. Enter in / m or / in 1-2 g every 24 hours or 0.5-1 g every 12 hours. Depending on the etiology of the disease, you can use IM in a dose of 250 mg once. The daily dose for newborns is 20-50 mg / kg; for children aged 2 months to 12 years - 20-100 mg / kg; multiplicity of administration 1 time / day. The duration of the course is determined individually. In patients with impaired renal function, correction of the dosing regimen is required with allowance for the CK values.
Maximum daily doses: for adults - 4 g, for children - 2 g.
SIDE EFFECT
On the part of the digestive system: nausea, vomiting, diarrhea, transient increase in hepatic transaminase activity, cholestatic jaundice, hepatitis, pseudomembranous colitis.
Allergic reactions: skin rash, itching, eosinophilia; rarely - angioedema.
From the hemopoietic system: with prolonged use in high doses, changes in the pattern of peripheral blood (leukopenia, neutropenia, thrombocytopenia, hemolytic anemia) are possible.
From the side of the blood coagulation system: hypoprothrombinemia.
From the side of the urinary system: interstitial nephritis.
Effects caused by chemotherapeutic action: Candidiasis.
Local reactions: phlebitis (with iv introduction), soreness at the injection site (with an / m introduction).
CONTRAINDICATIONS
Hypersensitivity to ceftriaxone and other cephalosporins.
PREGNANCY AND LACTATION
Adequate and strictly controlled safety studies of ceftriaxone in pregnancy have not been conducted.
The use of ceftriaxone in pregnancy and during lactation is possible in cases where the intended benefit of therapy for the mother exceeds the potential risk to the fetus.
Ceftriaxone is excreted in breast milk in low concentrations.
In experimental animal studies, there were no teratogenic and embryotoxic effects of ceftriaxone.
APPLICATION FOR FUNCTIONS OF THE LIVER
In patients with impaired renal function, correction of the dosing regimen is required with allowance for the CK values.
With caution apply for severe impairment of kidney function.
APPLICATION FOR CHILDREN
In newborns with hyperbilirubinemia, especially in preterm infants, use under strict medical supervision is possible.
SPECIAL INSTRUCTIONS
In patients with hypersensitivity to penicillins, allergic reactions to cephalosporin antibiotics are possible.
With caution apply for severe impairment of kidney function.
Ceftriaxone solutions should not be mixed or administered concomitantly with other antimicrobial agents or solutions.
In newborns with hyperbilirubinemia, especially in preterm infants, use under strict medical supervision is possible.
DRUG INTERACTION
Ceftriaxone, suppressing the intestinal flora, interferes with the synthesis of vitamin K. Therefore, with the simultaneous use with drugs that reduce platelet aggregation (NSAIDs, salicylates, sulfinpyrazone), the risk of bleeding increases. For the same reason, with simultaneous use with anticoagulants, there is an increase in anticoagulant activity.
With simultaneous use with "loop" diuretics, the risk of developing nephrotoxic action increases.
